CMS Updates Coverage Policy for Non-Implantable Pelvic Floor Electrical Stimulators (NCD 231)
CMS has issued a modification to National Coverage Determination 231, governing non-implantable pelvic floor electrical stimulators classified under the Durable Medical Equipment benefit category. This update reinforces and clarifies the specific clinical criteria Medicare requires before this device is covered—criteria that many billing teams get wrong at the point of prior authorization or claim submission. If your practice treats urinary incontinence or manages DME orders for urology, urogynecology, or physical therapy patients, this policy directly affects your revenue cycle.
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Non-Implantable Pelvic Floor Electrical Stimulator |
| Policy Code | NCD 231 |
| Change Type | Modified |
| Effective Date | 2026-03-12 |
| Impact Level | Medium |
| Specialties Affected | Urology, Urogynecology, Physical Therapy, Obstetrics & Gynecology, DME Suppliers |
| Key Action | Audit documentation workflows to confirm a four-week PME trial failure is explicitly recorded before ordering or billing for the device. |
What CMS NCD 231 Covers: Pelvic Floor Electrical Stimulation for Urinary Incontinence
Non-implantable pelvic floor electrical stimulators deliver neuromuscular electrical stimulation through the pelvic floor. The clinical goal is strengthening and exercising pelvic floor musculature—typically through vaginal or anal probes connected to an external pulse generator.
These devices are not one-size-fits-all. Stimulation parameters vary significantly across patients and diagnoses: stimulus frequency (measured in Hz), intensity or amplitude (measured in mA), pulse duration, duty cycle, daily treatment sessions, days per week, session length, and total duration of use can all differ. Whether treatment occurs in a clinic or home setting also affects how coverage rules apply.
CMS's policy under NCD 231 applies to this entire category of non-implantable devices—regardless of the specific parameter configuration a provider selects.
Medicare Coverage Criteria: Who Qualifies Under NCD 231
This is where most claims run into trouble. CMS covers pelvic floor electrical stimulation with a non-implantable stimulator under two specific conditions—both must be met simultaneously:
1. Diagnosis must be stress and/or urge urinary incontinence
The policy limits coverage to these two incontinence types. Mixed incontinence (stress + urge components together) also falls within scope. Overflow incontinence or incontinence with a neurological etiology is not addressed as a covered indication in this policy.
2. The patient must be cognitively intact
Cognitive status is an explicit coverage requirement. Patients with significant cognitive impairment are not eligible for coverage under NCD 231, as the effective use of pelvic floor stimulation devices requires patient cooperation and comprehension.
3. The patient must have failed a documented trial of pelvic muscle exercise (PME) training
This is the most frequently missed documentation requirement. CMS defines a failed PME trial precisely:
No clinically significant improvement in urinary continence after completing four weeks of an ordered plan of pelvic muscle exercises designed to increase periurethral muscle strength.
All three elements must be documented: the order for PME, the four-week duration, and the lack of clinically significant improvement. A patient who simply declines PME or has not been formally enrolled in an ordered program does not meet this threshold.
What NCD 231 Does Not Cover
CMS's coverage language is specific rather than broad, which means anything outside the defined criteria is not covered. Billing teams should flag these scenarios at intake:
- Patients with fecal incontinence (not addressed in NCD 231's covered indications)
- Patients who are cognitively impaired
- Patients who have not completed a four-week, physician-ordered PME program
- Patients with incomplete PME documentation, even if the trial was completed clinically
The policy does not designate pelvic floor electrical stimulation as experimental or investigational for its covered indications—this is an established covered benefit when criteria are met.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
Affected Codes
The policy document for NCD 231 does not list specific CPT or HCPCS codes. Billing teams should work directly with their DME supplier partners and consult the applicable HCPCS code set for non-implantable electrical stimulators, and verify coverage under the DME benefit category with their MAC (Medicare Administrative Contractor). No ICD-10-CM codes are enumerated in the policy document.
Note: The absence of specific codes in the NCD does not mean claims can be submitted without codes—it means code selection must be validated through your MAC's local coverage articles or the HCPCS code lookup tool. Contact your MAC directly to confirm the applicable HCPCS code for the specific device being ordered.
Documentation Checklist: Meeting CMS Medical Necessity Requirements
Before submitting any claim or DME order for a non-implantable pelvic floor electrical stimulator under NCD 231, the clinical record must support all of the following:
| Requirement | Documentation Needed |
|---|---|
| Diagnosis of stress and/or urge urinary incontinence | ICD-10 diagnosis code, clinical notes |
| Cognitive intact status | Provider attestation or clinical notation |
| Ordered PME program | Signed order with start date and exercise protocol |
| Four-week PME trial completed | Progress notes spanning the full four weeks |
| No clinically significant improvement | Provider's documented clinical assessment post-trial |
If any row in this table is missing from the chart, the claim is at high risk of denial.
What Your Billing Team Should Do
| # | Action Item |
|---|---|
| 1 | Audit your current intake and order workflow before March 12, 2026. Review how PME trial documentation is captured in your EHR. If the four-week trial and outcome assessment aren't built into your referral or order template, add them now—not after a denial wave. |
| 2 | Confirm cognitive status documentation is part of your standard intake for urinary incontinence patients. This requirement is easy to overlook because it's rarely discussed in clinical training. Add a cognitive status notation field to your DME order forms or referral checklists. |
| 3 | Contact your MAC to confirm applicable HCPCS codes. Since NCD 231 does not enumerate specific codes, your MAC's local coverage article is the authoritative source for code selection. This is especially important for DME suppliers billing under the competitive bidding program. |
| 4 | Train referring providers on the PME trial definition. Many denials for this device come not from billing errors but from clinical documentation gaps. A brief one-page provider education sheet on the four-week PME requirement and what "no clinically significant improvement" must look like in the record will pay for itself quickly. |
| 5 | Review any claims submitted in the 90 days before the effective date. If your practice has been submitting claims without full PME documentation, pull a report and assess your exposure before the modification goes live. |
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.